Package 76420-534-30

{"route": ["SUBLINGUAL"], "spl_id": "f33905ee-0218-1314-e053-2a95a90a25c7", "openfda": {"unii": ["56W8MW3EN1", "5Q187997EE"], "rxcui": ["351267"], "spl_set_id": ["597cbc69-84b1-4255-bed9-53d0c6dc2134"], "manufacturer_name": ["Asclemed USA, Inc."]}, "finished": true, "packaging": [{"sample": false, "description": "30 TABLET in 1 BOTTLE, PLASTIC (76420-534-30)", "package_ndc": "76420-534-30", "marketing_start_date": "20230127"}], "brand_name": "BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE", "product_id": "76420-534_f33905ee-0218-1314-e053-2a95a90a25c7", "dosage_form": "TABLET", "pharm_class": ["Opioid Antagonist [EPC]", "Opioid Antagonists [MoA]", "Partial Opioid Agonist [EPC]", "Partial Opioid Agonists [MoA]"], "product_ndc": "76420-534", "dea_schedule": "CIII", "generic_name": "BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE", "labeler_name": "Asclemed USA, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE", "active_ingredients": [{"name": "BUPRENORPHINE HYDROCHLORIDE", "strength": "8 mg/1"}, {"name": "NALOXONE HYDROCHLORIDE DIHYDRATE", "strength": "2 mg/1"}], "application_number": "ANDA209069", "marketing_category": "ANDA", "marketing_start_date": "20210122", "listing_expiration_date": "20261231"}